ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016 ACR/ARHP Annual Meeting
    • 2015 ACR/ARHP Annual Meeting
    • 2014 ACR/ARHP Annual Meeting
    • 2013 ACR/ARHP Annual Meeting
    • 2012 ACR/ARHP Annual Meeting
    • 2011 ACR/ARHP Annual Meeting
    • 2010 ACR/ARHP Annual Meeting
    • 2009 ACR/ARHP Annual Meeting
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Adalimumab and juvenile idiopathic arthritis (JIA)"

  • Abstract Number: 385 • 2016 ACR/ARHP Annual Meeting

    Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn’s Disease

    Gerd Horneff1, Marieke M. B. Seyger2, Dilek Arikan3, Jasmina Kalabic4, Jaclyn K. Anderson3, Andreas Lazar5, David A. Williams3, Chen Wang3, Rita Tarzynski-Potempa3 and Jeffrey S. Hyams6, 1Asklepios Kliniken GmbH, Hamburg, Germany, 2Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, 3AbbVie Inc., North Chicago, IL, 4AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 5AbbVie Deutschland GmbH & Co. KG, North ChicagoLudwigshafen, IL, Germany, 6Connecticut Children’s Medical Center, Hartford, CT

    Background/Purpose: Adalimumab (ADA) is a tumor necrosis factor (TNF) inhibitor used for treatment of chronic immune diseases. The safety of ADA treatment in pediatric patients…
  • Abstract Number: 2452 • 2015 ACR/ARHP Annual Meeting

    Clinical and Functional Outcomes in Patients with Polyarticular Juvenile Idiopathic Arthritis Following Treatment with Adalimumab

    Daniel J. Kingsbury1, Pierre Quartier2, G Horneff3, Kirsten Minden4, Mary Toth5, Nupun A. Varothai6, Anabela Cardoso7 and Jasmina Kalabic6, 1Randall Children's Hospital at Legacy Emanuel, Portland, OR, 2Hopital Necker-Enfants Malades, Paris, France, 3Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, 4Kinderklinik der Charite, Otto-Heubner Centrum, Berlin, Germany, 5Akron Children's Hospital, Akron, OH, 6AbbVie, North Chicago, IL, 7AbbVie, Amadora, Portugal

    Background/Purpose: The Juvenile Arthritis Disease Activity Score (JADAS) is increasingly accepted for defining a treat-to-target strategy in patients (pts) with juvenile idiopathic arthritis (JIA)1 The…
  • Abstract Number: 2428 • 2015 ACR/ARHP Annual Meeting

    Efficacy and Safety of Adalimumab in Adult Patients with Polyarticular Juvenille Idiopathic Arthritis

    Daniel Lovell1,2, Nicolino Ruperto3, Andreas Reiff4, Lawrence Jung5, Katerina Jarosova6, Pierre Quartier7, Christy Sandborg8, John F. Bohnsack9, Dirk Elewaut10, Ivan Foeldvari11, Joseph Rovensky12, Edward H. Giannini2, Nupun A. Varothai13, Jasmina Kalabic13 and Alberto Martini14,15,16, 1PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2PRCSG, Cincinnati, OH, 3Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, 4Children's Hospital, Los Angeles, CA, 5Pediatric Rheumatology, Children's National Med Ctr, Washington, DC, 6Revmatologicky ustav, Prague, Czech Republic, 7Hospital Necker Enfants Malades, Paris, France, 8Stanford University Medical Center, Standford, CA, 9Pediatrics, University of Utah Health Sciences Center, Salt Lake City, UT, 10Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, VIB, Ghent University and Ghent University Hospital, Ghent, Belgium, 11Hamburger Zentrum für Kinder-und Jugendrheumatologie, Hamburg, Germany, 12The National Institute of Rheumatic Diseases, Piestany, Slovakia, 13AbbVie, North Chicago, IL, 14University of Genova, Genova, Italy, 15Department of Pediatrics, University of Genova, Genova, Italy, 16Istituto Gaslini-PRINTO, Genova, Italy

    Background/Purpose: The diagnosis of polyarticular JIA (pJIA) is made in childhood but the disease and the diagnosis are carried into adulthood. Adults with pJIA have…
  • Abstract Number: 279 • 2013 ACR/ARHP Annual Meeting

    Safety and Effectiveness Of Adalimumab In Children With Polyarticular Juvenile Idiopathic Arthritis Aged 2 To <4 Years Or ≥4 Years Weighing <15 Kg

    Daniel J. Kingsbury1, Pierre Quartier2, Vipin Arora3, Jasmina Kalabic4, Hartmut Kupper4 and Neelufar Mozaffarian3, 1Randall Children's Hospital at Legacy Emanuel, Portland, OR, 2Pediatria II, Istituto Giannina Gaslini, Genoa, Italy, 3AbbVie, North Chicago, IL, 4AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany

    Background/Purpose: Adalimumab (ADA) is approved for use in moderate to severe juvenile idiopathic arthritis (JIA) in patients (pts) ≥4 years (yrs) old in the US,…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Annual Meeting in Atlanta, Georgia

© COPYRIGHT 2019 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.